MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals, Inc. - Common Stock (NQ:LBPH)

59.98 UNCHANGED
Last Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Longboard Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Bright Minds Biosciences Stock Surges Almost 1,500%
Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news. 
Via MarketBeat
News headline image
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
News headline image
LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
News headline image
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story